FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc. (“Licensee”) executed October 1, 2021 for a COVID-19 Vaccine (the “Agreement”), is made by Licensor and Licensee,
LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • November 7th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • Pennsylvania
This License Agreement (this “Agreement”) is made and is effective this 1st day of October 2021, (the “Effective Date”) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (“Licensor”) and Curative Biotechnology, Inc. (hereinafter CUBT), a Delaware corporation (“Licensee”), and David Horn, LLC as Licensor to MABT, and their respective legitimate successors and/or assigns. Licensors and Licensee are each referred to as a “Party” and collectively referred to as the “Parties.”
LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • November 7th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • Pennsylvania
This License Agreement (this “Agreement”) is made and is effective this 30th day of September, 2020, (the “Effective Date”) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (“Licensor”) and Connectyx (hereinafter CTYX) Technologies Holdings Group, Inc., a Florida corporation (“Licensee”), and David Horn, LLC as Licensor to MABT, and their respective legitimate successors and/or assigns. Licensors and Licensee are each referred to as a “Party” and collectively referred to as the “Parties.”
FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
THIS IS THE FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement for rabies immunotherapy (the “Agreement”) between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc., formerly Connectyx, (“Licensee”) originally executed September 30th, 2020.
